NEWS
Degron Therapeutics ("Degron"), a biotechnology company developing a new class of molecular glue degrader (MGD) medicines targeting previously undruggable proteins, announced that it has received clearance on January 29, 2025, from the U.S. Food and Drug Administration (FDA) the company’s Investigational New Drug (IND) application for DEG6498, a first-in-class HuR (Human antigen R) molecular glue degrader investigational drug. Degron is initiating clinical development globally in patients with colorectal, lung, hepatocellular and other types of solid tumors.
DEG6498 is the leading program in Degron's pipeline of novel MGD therapeutics, targeting HuR, a previously undruggable RNA-binding protein playing critical roles in driving cancer, inflammatory and metabolic disorders. “FDA clearance of our first IND is a significant milestone for our company. It validates the ability for our GlueXplorer platform to discover and validate novel molecular glue degraders for targets that are previously undruggable, and illustrates the rapid growth of the company from a discovery engine to a clinical stage company,” said Lily Zou, Ph.D., CEO of Degron Therapeutics. “Degron is the first company to discover a molecular glue degrader for HuR, and advances it into clinical development. We are excited about the potential of this program to bring new treatment for patients and demonstrate MGD as a new therapeutic approach for undruggable targets.”
Degron’s proprietary GlueXplorer® platform has included more than 10,000 structurally differentiated MGD compounds with associated compound-induced proximity and degradation data. This biology-backed library, combined with the company's comprehensive screening and validation systems, enables the discovery of novel targets and the optimization of new MGDs. In addition to the HuR program, the company is advancing multiple MGD programs addressing historically intractable but extensively characterized disease targets. Degron's strategic goal is to continuously deliver breakthrough therapies that improve human health, benefiting patients worldwide.
About DEG6498
DEG6498 is a potent and orally bioavailable small molecule molecular glue degrader that induces the interaction between the E3 ubiquitin ligase component cereblon (CRBN) and the RNA binding protein Human antigen R (HuR), leading to the targeted degradation of HuR protein. Our early clinical development program aims to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamics, and anti-tumor activity of DEG6498 in multiple solid tumors.
About Degron Therapeutics
Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its proprietary molecular glue-based targeted protein degradation drug discovery platform. The company's unique GlueXplorer® platform has created a rapidly expanding IP-protected compound library and screening and validation systems to discovery a new class of small-molecule medicines that target previously undruggable disease targets. The company's pipeline includes a growing number of clinical and preclinical programs for oncology, inflammation, neurology, and metabolic diseases. For more information, visit www.degrontx.com.
